Revolution Medicines (RVMD) Receivables - Other (2019 - 2020)
Revolution Medicines (RVMD) posted quarterly Receivables - Other of $6.4 million for Q4 2020, down 26.83% year-over-year from $8.7 million in Q1 2020, and down 31.25% quarter-over-quarter from $9.3 million in Q3 2020.
Revolution Medicines (RVMD) Receivables - Other (2019 - 2020) Analysis & Trends
Revolution Medicines' Receivables - Other history runs 2 years deep, the most recent figure standing at $6.4 million for Q4 2020.
- In Q4 2020, Receivables - Other fell 26.83% year-over-year to $6.4 million; the TTM figure through Dec 2020 stood at $6.4 million (down 26.83% YoY), while the FY2020 annual figure was $6.4 million, down 26.83% from the prior year.
- Receivables - Other for Q4 2020 stood at $6.4 million, down from $9.3 million in the prior quarter.
- The five-year high for Receivables - Other was $9.3 million in Q3 2020, with the low at $6.4 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 6.39 Mn |
| Dec 31, 2020 | 6.39 Mn |
| Sep 30, 2020 | 9.30 Mn |
| Sep 30, 2020 | 9.30 Mn |
| Jun 30, 2020 | 7.33 Mn |
| Jun 30, 2020 | 7.33 Mn |
| Mar 31, 2020 | 8.45 Mn |
| Mar 31, 2020 | 8.45 Mn |
| Dec 31, 2019 | 8.74 Mn |
| Dec 31, 2019 | 8.74 Mn |